Search Videos and More
Video
Updated Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Clinical Trials
Sara Tolaney, MD, MPH discusses updated standardized definitions for efficacy endpoints in adjuvant breast cancer clinical trials: STEEP Version 2.0.
News
Study Pairs Two Forms of Immunotherapy in Patients with Advanced Kidney Cancer
T cells revved up to attack tumors are turned into an army of loiterers. Cells keenly attuned to signals of infection or disease fail to pick up the faint notes of cancer. A clinical trial led by Dana-Farber researchers is addressing both of these issues in patients who have undergone surgery for kidney cancer but have a high risk of recurrence.
News
Dana-Farber Cancer Institute Establishes the David Liposarcoma Research Initiative
Dana-Farber Cancer Institute announced that The Rossy Foundation has committed $10 million to establish the David Liposarcoma Research Initiative.
News
Study Reveals Factor That Determines ‘Fate’ of Cancer Cells When Tumor Suppressor Gene Function is Restored
Many cancers develop from cells that have a malfunctioning tumor suppressor gene, p53, which normally helps control unchecked cell growth and prevent cancer.
News
Cancer Screenings Rebounded in Late 2020 After COVID-related Decline, but Racial and Economic Disparities Remain for Some Tests
The numbers of cancer screening tests rebounded sharply in the last quarter of 2020, following a dramatic decline in the first months of the COVID-19 pandemic, at one large hospital system in the Northeastern United States. These findings were released in a study published in Cancer Cell. The research also found an increase in racial and socioeconomic disparities among users of some screening tests during the pandemic.
News
New Research Uncovers How Cancers with Common Gene Mutation Develop Resistance to Targeted Drugs
Multiple acquired resistance mechanisms discovered for cancers with KRASG12C mutation after treatment with KRASG12C inhibitors.
Podcast
FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
Dr. Munshi discusses the significance of the FDA approval of ide-cel in relapsed/refractory multiple myeloma, data from the KarMMa trial, which served as the basis for the approval, and next steps for CAR T-cell therapy in the field.
News
Antibiotic Novobiocin Found to Kill Tumor Cells with DNA-Repair Glitch
An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute scientists shows.
News
Red Meat Consumption May Promote DNA Damage-associated Mutations in Patients with Colorectal Cancer
Genetic mutations indicative of DNA damage were associated with high red meat consumption and increased cancer-related mortality in patients with colorectal cancer, according to a study led by Dana-Farber Cancer Institute researchers and published in Cancer Discovery, a journal of the American Association for Cancer Research.
News
“45 is the New 50” as Age for Colorectal Cancer Screening is Lowered
Prompted by a recent alarming rise in cases of colorectal cancer in people younger than 50, an independent expert panel has recommended that individuals of average risk for the disease begin screening exams at 45 years of age instead of the traditional 50.
Video
COVID-19 Vaccine Study in Cancer Patients
Dana-Farber researchers are leading a study that looks at the effects of the COVID-19 vaccine in cancer patients.
News
New ‘Druggable’ Genetic Targets Identified in Rare Type of Bile Duct Cancer
Scientists are beginning to make inroads into treating cholangiocarcinoma, a rare, lethal cancer of the bile ducts, with precision drugs. Last year, the first targeted drug for some patients with the disease was approved.